Article
Medical Laboratory Technology
Michael Vogeser
Summary: Therapeutic drug monitoring plays a crucial role in medicine, yet it is often overlooked in laboratory medicine. A goal for laboratory medicine in the 21st century should be enabling clinicians to verify the presence of the right drug in the right patient with appropriate blood concentrations for each compound.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Paola E. Oceguera-Basurto, Edgar B. Figueroa-Ochoa, Luis A. Anguiano-Sevilla, Dante R. Sanchez-Ramirez, Antonio Quintero-Ramos, Alicia del Toro-Arreola, Rocio I. Lopez-Roa, Pablo Taboada, Antonio Topete, Adrian Daneri-Navarro
Summary: Breast cancer has become the most diagnosed cancer, with a high mortality rate among women. Selective estrogen-receptor modulators (SERMs) have been used for the prevention and treatment of estrogen receptor-positive breast cancer, but their long-term oral administration has been associated with toxicity and side effects. This study explores the use of a polymeric gel-like solution as a topical administration route for the active metabolite of tamoxifen (EDX), which has shown significant antitumor efficacy and reduced toxicity compared to oral tamoxifen. This novel administration route could have a strong impact on breast cancer prevention and treatment.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Public, Environmental & Occupational Health
Bin Lin, Yangmin Hu, Ping Xu, Tao Xu, Chunyan Chen, Le He, Mi Zhou, Zhangzhang Chen, Chunhong Zhang, Xuben Yu, Luo Fang, Junfeng Zhu, Yanlan Ji, Qun Lin, Hengbin Cao, Youqin Dai, Xiaoyan Lu, Changcheng Shi, Li Li, Changjiang Wang, Xumei Li, Qiongyan Fang, Jing Miao, Zhengyi Zhu, Guangyong Lin, Haichao Zhan, Shiwen Lv, Yalan Zhu, Xinjun Cai, Yin Ying, Meng Chen, Qiong Xu, Yiwen Zhang, Yubin Xu, Pea Federico, Saiping Jiang, Haibin Dai
Summary: Through in-depth research on Linezolid, a team of experts from various disciplines has formed a consensus on the therapeutic drug monitoring and safe use of Linezolid.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Medical Laboratory Technology
Pasindu Wickramarachchi, Jessica M. Boyd, Dennis J. Orton
Summary: The study defined the biological variability of clozapine metabolism and found a significant relationship between kidney function and levels of CLO and NCLO.
CLINICA CHIMICA ACTA
(2022)
Review
Instruments & Instrumentation
Mayur Aalhate, Srushti Mahajan, Hoshiyar Singh, Santosh Kumar Guru, Pankaj Kumar Singh
Summary: Breast cancer is the most commonly diagnosed cancer in women worldwide, and early-stage non-metastatic cases have a high cure rate. However, there is a high risk of recurrence with endocrine therapy. Nanomedicine, which improves drug delivery and reduces toxicity, has become a promising approach for breast cancer treatment.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2023)
Review
Oncology
Angelica Ferrando-Diez, Eudald Felip, Anna Pous, Milana Bergamino Sirven, Mireia Margeli
Summary: In recent years, the development of anti-HER2 treatments has improved the landscape of HER2-positive breast cancer. However, relapse remains a major issue. This review focuses on the milestones that have impacted the disease and highlights the importance of understanding the underlying molecular biology for optimizing treatment options. The review also discusses the role of triple-positive disease and modulation of the immune response in treatment and prognosis.
Article
Medicine, Research & Experimental
Ivana Kacirova, Milan Grundmann, Hana Brozmanova
Summary: The study found a significant correlation between maternal serum levels and milk levels of carbamazepine and its metabolite 10,11-epoxide. Concurrent use of enzyme-inducing antiepileptic drugs significantly increased the maternal apparent oral clearance of carbamazepine.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Oncology
William Sebastian, Lauren Forchette, Kelsey Donoughe, Yibei Lun, Anisha Verma, Tuoen Liu
Summary: In this review paper, various important aspects of hormone receptor (HR)-positive breast cancer were discussed, including HR structure and signaling, genetics (epigenetics and gene mutations), gene expression-based assays, traditional and new drugs for treatment, and new technological uses in diagnosis and treatment. Particularly, the commonly mutated genes and abnormally methylated genes in HR-positive breast cancer were summarized, and the common gene expression-based assays used in breast cancer as prognostic and/or predictive tools were compared in detail. These topic discussions have not been fully described and summarized within other research or review articles.
Review
Medical Laboratory Technology
Stephanie E. Reuter, Sophie L. Stocker, Jan-Willem C. Alffenaar, Sara Baldelli, Dario Cattaneo, Graham Jones, Birgit C. P. Koch, Danijela Kocic, Sumith K. Mathew, Mariadelfina Molinaro, Michael Neely, Indy Sandaradura, Deborah J. E. Marriott
Summary: Individualized vancomycin dosing based on therapeutic drug monitoring (TDM) data is proven to be more effective than fixed or empirical dosing strategies. Area-under-the-curve (AUC(24))-guided TDM is increasingly supported for vancomycin dosing decisions in patients receiving treatment for more than 48 hours. However, institutional barriers may hinder the implementation of AUC(24)-guided dosing, requiring additional effort to transition from trough-based strategies. Proper documentation, storage, transport, laboratory analysis, and data reporting are essential for appropriate interpretation of TDM data to guide vancomycin dosing recommendations. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology provides recommendations for best clinical practice in vancomycin TDM.
THERAPEUTIC DRUG MONITORING
(2022)
Review
Endocrinology & Metabolism
Jie Yuan, Li Yang, Zhi Li, Hua Zhang, Qun Wang, Jun Huang, Bei Wang, Chakrabhavi Dhananjaya Mohan, Gautam Sethi, Geng Wang
Summary: Endocrine therapy is essential for hormone-positive breast cancers, but resistance to therapy poses a significant challenge. Understanding the molecular mechanisms of resistance and the tumor microenvironment is crucial for developing new treatment strategies.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Pharmacology & Pharmacy
Sarah Baklouti, Peggy Gandia, Didier Concordet
Summary: This article proposes a methodology to correct the bias and improve the precision of empirical Bayes estimates (EBEs) used in therapeutic drug monitoring (TDM). The method, based on a bias correction and selection of the lambda parameter, outperforms EBE in terms of bias and precision. The results demonstrate the effectiveness of this approach for different drugs.
CLINICAL PHARMACOKINETICS
(2022)
Article
Pharmacology & Pharmacy
Sonja E. Zapke, Stefan Willmann, Scott-Oliver Grebe, Kristin Menke, Petra A. Thurmann, Sven Schmiedl
Summary: The study compared the performance of a PBPK model for cyclosporine and found that 86% of predicted cyclosporine trough levels deviated less than twofold from observed values. The model did not fully cover the high intra-individual variability of observed cyclosporine levels. Considering clinical and additional patient-related factors may improve the model's performance.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Ehab S. EL Desoky, Amira F. Taha, Heba Salah Mousa, Abeer Ibrahim, Medhat A. Saleh, Mohamed A. Abdelrady, Mohammad Salem Hareedy
Summary: This pilot study aims to assess the clinical benefits of measuring the endoxifen active metabolite of tamoxifen in breast cancer patients during therapy. The study found that there is wide inter-individual variability in the concentration of the metabolite, and this variability is related to both adverse effects and cancer recurrence. Monitoring the serum concentration of endoxifen can help optimize tamoxifen therapy and control its adverse effects and cancer recurrence.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Biochemistry & Molecular Biology
Mayuko Ikarashi, Junko Tsuchida, Masayuki Nagahashi, Shiho Takeuchi, Kazuki Moro, Chie Toshikawa, Shun Abe, Hiroshi Ichikawa, Yoshifumi Shimada, Jun Sakata, Yu Koyama, Nobuaki Sato, Nitai C. Hait, Yiwei Ling, Shujiro Okuda, Kazuaki Takabe, Toshifumi Wakai
Summary: Elevated plasma levels of S1P are associated with larger tumor size, lymph node metastasis, and advanced cancer stage in ER-positive breast cancer patients, indicating a role in cancer progression. Treatment with FTY720, a functional antagonist of S1P receptors, showed promising results in suppressing viability of hormone therapy-resistant cells, suggesting a potential new therapeutic strategy for ER-positive breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Minwoo Kang, Jong Il Shin, Sangjin Han, Jung Young Kim, Jeonghoon Park, Kwang Il Kim, Joo Hyun Kang, Tae Sup Lee
Summary: This study evaluated the feasibility of monitoring therapeutic response using Zr-89-DFO-pertuzumab immuno-PET imaging agent for HER2-targeted therapy. The results showed that Zr-89-DFO-pertuzumab can clearly visualize HER2 expressing tumors and demonstrated significant HER2 downregulation in 17-DMAG treated tumors.